Decision: Favourable

Study Title:

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis

  • NREC Code:

    22-NREC-CT-161

  • Decision:

    Favourable

  • Meeting Date:

    19/10/2022

  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Katherine O'Reilly

  • PI Institution:

    Mater Misericordiae University Hospital

  • Sponsor:

    Horizon Therapeutics Ireland DAC

Scroll to Top